Systematic review and meta-analysis reveals degarelix has higher adverse events in prostate cancer, indicating cardiovascular and musculoskeletal safety benefits.
While degarelix is associated with higher overall AE rates, it provides significant benefits in terms of cardiovascular and musculoskeletal safety, rapid testosterone suppression, and lower urinary AEs.
No takes yet. Share an insight, caveat, or question.
Chai et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: